Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.
暂无分享,去创建一个
D. Sargent | J. Sloan | R. Goldberg | A. Shields | S. Alberts | S. Nair | M. Mahoney | E. Chan | S. Gill | M. Kahlenberg | J. Hubbard | H. Liu